Andrew Tsai
Stock Analyst at Jefferies
(0.34)
# 4,112
Out of 4,876 analysts
20
Total ratings
23.53%
Success rate
-34.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $54 | $17.11 | +215.60% | 2 | Jun 16, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $93.82 | +17.25% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $2.53 | -1.19% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $103.36 | +93.50% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.54 | +45.63% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.61 | +2,031.15% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $11.43 | +206.21% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.31 | +1,328.57% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $1.97 | +661.42% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.82 | +265.45% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $3 | $0.30 | +916.95% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.95 | +151.57% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.20 | +1,127.27% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $32.40 | -29.01% | 1 | Jun 1, 2020 |
Sarepta Therapeutics
Jun 16, 2025
Maintains: Buy
Price Target: $125 → $54
Current: $17.11
Upside: +215.60%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $93.82
Upside: +17.25%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $2.53
Upside: -1.19%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $103.36
Upside: +93.50%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.54
Upside: +45.63%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.61
Upside: +2,031.15%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $11.43
Upside: +206.21%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.31
Upside: +1,328.57%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $1.97
Upside: +661.42%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.82
Upside: +265.45%
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.30
Upside: +916.95%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $7.95
Upside: +151.57%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $2.20
Upside: +1,127.27%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $32.40
Upside: -29.01%